Fennec Pharmaceuticals Inc.
NASDAQ:FENCBiotechnology
-$0.12 today
- Market cap
- $470.62M
- Beta
- 1.08
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$0.24
Volume 0.59M
Average 0.26M
FENC Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Fennec Pharmaceuticals Inc.NASDAQ: FENC
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $26K fell 33.3% year over year, ahead of the -59.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 2499.9% from the prior quarter. Over 3 fiscal years it compounded at -11.6% a year.
Context
- Depreciation & amortization amounted to 0.2% of revenue in FY2025, down 1.8 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.3% holds above the trailing-twelve-month pace of -59.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 103K USD
- Year-over-year change
- -89.3%
- 4-year CAGR
- +59.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103K | -89.3% |
| FY2024 | 2024-12-31 | 959K | +234.1% |
| FY2023 | 2023-12-31 | 287K | +92.6% |
| FY2022 | 2022-12-31 | 149K | +831.3% |
| FY2021 | 2021-12-31 | 16K | — |
Depreciation & Amortization vs competitors
How FENC compares with its peers on the latest reported figures
- FENC's LTM Mar 2026 depreciation & amortization of $103K is the smallest of the 11 companies compared; the peer median is $934K.
- Its year-over-year change of -59.6% is the 10th highest of 11, against a peer median of +2.1%.
- Depreciation & amortization amounts to 0.2% of revenue for FENC, versus a peer median of 18.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $4.95M | +56.5% | +19.6% | 7.2% | |
| LTM Mar 2026 | $3.13M | -28.6% | +0.0% | 27.9% | |
| LTM Mar 2026 | $2.42M | +13.1% | +32.0% | 136.2% | |
| LTM Mar 2026 | $1.53M | +180.4% | +0.4% | 9.2% | |
| LTM Mar 2026 | $718K | -3878.9% | — | — | |
| LTM Mar 2026 | $334K | +5.4% | +13.8% | 1.0% | |
| LTM Mar 2026 | $265K | -23.0% | -13.8% | — | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $263.36K | +65.0% | +17.8% | — |
| LTM Mar 2026 | $226K | -16.3% | +27.5% | 383.1% | |
| LTM Mar 2026 | $103K | -59.6% | -11.6% | 0.2% | |
| Peer median (excluding FENC) | $934K | +2.1% | +17.8% | 18.6% | |
Competitors are the stored peer set for FENC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.35M) | (23.71M) | (16.05M) | (436K) | (10.27M) |
| Depreciation & Amortization | 16K | 149K | 287K | 959K | 103K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.01M | 4.22M | 5.35M | 5.06M | 7.03M |
| Change in Working Capital | (138K) | (509K) | (8.17M) | (7.33M) | (15.09M) |
| Accounts Receivables | 0 | (1.55M) | (7.27M) | (7.87M) | (12.66M) |
| Inventory | 0 | (576K) | (1.58M) | 579K | (1.3M) |
| Accounts Payables | 0 | 0 | 0 | 0 | 1.42M |
| Other Working Capital | (138K) | 1.61M | 683K | (35K) | (2.55M) |
| Other Non-Cash Items | (769K) | 1.8M | 1.43M | 28.73M | 5.76M |
| Operating Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 5M | 20.17M | 5M | (13M) | (19.82M) |
| Common Stock Issued | 33K | 0 | 0 | 0 | 45.01M |
| Common Stock Repurchased | 0 | (194K) | (78K) | (176K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (55K) | 753K | 1.72M | (439K) | (2.57M) |
| Financing Cash Flow | 4.98M | 20.73M | 6.64M | (13.62M) | 22.63M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.24M) | 2.67M | (10.51M) | 13.37M | 10.15M |
| Free Cash Flow | (14.22M) | (18.06M) | (17.14M) | 26.98M | (12.47M) |
Fennec Pharmaceuticals Inc.
NASDAQ:FENC
Intrinsic Alpha fair value
Locked
Current Price
$13.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.